Sri Kosaraju

Sri Kosaraju has served on our Board since August 2021. Since October 2020, Mr. Kosaraju has served as the Chief Executive Officer and President of Inscripta, Inc., a privately-held digital genome engineering company. Prior to joining Inscripta, Mr. Kosaraju was President of Penumbra, Inc., which he joined as CFO in May 2015. Earlier, Mr. Kosaraju spent 16 years at J.P. Morgan, where he was most recently Head of Healthcare Equity Capital Markets and Co-Head of Technology Equity Capital Markets. While at J.P. Morgan, he worked closely with and advised many emerging, high-growth life science and tech companies. In addition to serving on the Board of Directors for Inscripta, Mr. Kosaraju also currently serves on the Board of Directors and is the Chair of the Audit Committee of 10x Genomics, Inc., a life science technology company building products to interrogate, understand and master biology to advance human health, and is on the Board of the non-profit Testing for America. Mr. Kosaraju earned his B.S in Mechanical Engineering from the Massachusetts Institute of Technology (MIT).